Pasireotide: a novel treatment for patients with acromegaly
Daniel Cuevas-Ramos,1 Maria Fleseriu2,3 1Department of Endocrinology and Metabolism, Neuroendocrinology Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; 2Department of Medicine (Endocrinology), 3Department of Neurolog...
Main Authors: | Cuevas-Ramos D, Fleseriu M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-01-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/pasireotide-a-novel-treatment-for-patients-with-acromegaly-peer-reviewed-article-DDDT |
Similar Items
-
Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
by: Mônica Gadelha, et al.
Published: (2020-02-01) -
Efficacy of pasireotide LAR for acromegaly: a prolonged real-world monocentric study
by: Vittoria Favero, et al.
Published: (2024-02-01) -
Pasireotide: A new option for treatment of acromegaly
by: Filiz Eksi Haydardedeoglu, et al.
Published: (2020-06-01) -
Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR
by: Peter Wolf, et al.
Published: (2022-11-01) -
Pasireotide in the Personalized Treatment of Acromegaly
by: Manel Puig-Domingo, et al.
Published: (2021-03-01)